Curis(NASDAQ) CRIS

Current Price$4.90

Market Cap$9.10M

Since IPO (2000)-100%

5 Year-100%

1 Year-87%

1 Month-35%

Curis last closing stock price
Metric	Price	Date
Last close	USD 4.67	2026-07-23

Curis stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-6.22%	USD 4.98	2026-07-16
1 month	-35.44%	USD 7.23	2026-06-23
3 month	-60.76%	USD 11.90	2026-04-24
Year to date	-76.34%	USD 19.74	2025-12-31
1 year	-87.17%	USD 36.40	2025-07-23
3 year	-98.51%	USD 312.88	2023-07-24
5 year	-99.84%	USD 2,988.00	2021-07-23
Since inception	-99.99%	USD 48,750.00	2000-08-01

Curis Financials at a Glance

Market Cap

$9.10M

Revenue (TTM)

$7.06M

Net Income (TTM)

-$21.17M

EPS (TTM)

-$23.88

P/E Ratio

-0.20

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$4.90

Volume

977

Open

$4.96

Price

$4.90

Volume

977

Open

$4.96

Previous Close

$4.90

Daily Range

$4.87 - $5.15

52-Week Range

$3.61 - $39.00

Estimated Earnings Date

Aug 4, 2026

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$4.90

Volume

977

Open

$4.96

Previous Close

$4.90

Daily Range

$4.87 - $5.15

52-Week Range

$3.61 - $39.00

Estimated Earnings Date

Aug 4, 2026

CRIS News

3 Top Stocks Under $5

Rich DupreyJan 24, 2017

Today’s Top Biotech Stories: Curis, Amgen, and Novartis

Leo SunMar 31, 2014

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Curis

Curis develops medicines for people with cancer.

Its main drugs aim to help patients with blood cancers and cancers involving the immune system.

These treatments target specific disease pathways to improve patient outcomes.

Products and Services

Emavusertib (CA-4948): Oral drug for blood cancers like lymphoma and leukemia.
CI-8993: Antibody treatment designed to help the immune system fight cancer.
Fimepinostat: Oral drug for certain aggressive lymphomas with genetic changes.
CA-170: Oral drug targeting immune checkpoints, aiming to help the body attack tumors.
CA-327: Early-stage cancer drug focused on immune system pathways.

Growth and Expansion

Formed partnership with Genentech and Roche for Erivedge commercialization (prior to 2025).
Sold Erivedge royalty rights in Q4 2025, ending product revenue from this source.
Ongoing collaboration with Aurigene Discovery Technologies for new cancer drug discovery.
Launched new clinical studies for emavusertib in 2025, expanding its use in blood cancers.

What Makes Curis Stand Out

Curis focuses on precision cancer drugs that target specific disease pathways. The company uses partnerships to share risk and access new technologies. Its pipeline includes both small molecule drugs and antibody treatments for rare cancers.

Five Things You Need to Know

Revenue was $1 million in Q4 2025, down 66% year-over-year.
Operating expenses rose to $5 million in Q4 2025, up 53.2% from 2024.
Net loss improved to $8 million in Q4 2025, a 15.8% year-over-year improvement.
Cash used in operations was $6 million in Q4 2025, improving 39.9% from 2024.

Bottom Line

Curis has shifted from earning royalties to focusing on developing new cancer drugs. The company faces funding challenges but continues to advance its pipeline through partnerships and clinical trials.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

James E. Dentzer, MBA

Website

www.curis.com

Headquarters

Lexington, MA 02421, US

CRIS Financials

Key Financial Metrics (TTM)

Gross Margin

99.45%

Operating Margin

-485.12%

Net Income Margin

-299.66%

Return on Equity

805.67%

Return on Capital

-464.72%

Return on Assets

-71.30%

Earnings Yield

-5.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.10M

Shares Outstanding

1.95M

Volume

977

Avg. Volume

172.70K

Financials (TTM)

Gross Profit

$7.02M

Operating Income

-$34.26M

EBITDA

-$20.46M

Operating Cash Flow

-$28.95M

Capital Expenditure

$0.00

Free Cash Flow

-$28.95M

Cash & ST Invst.

$15.00M

Total Debt

$1.34M

Curis Performance Analysis

Curis annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 10,162,000	-4.6%
2023	2023-12-31	USD 10,023,000	-1.4%
2024	2024-12-31	USD 10,908,000	8.8%
2025	2025-12-31	USD 9,443,000	-13.4%

Curis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	15.5%
Q3	2025-09-30	15.5%
Q4	2025-12-31	-64.2%
Q1	2026-03-31	-100.0%

Curis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -242.73	22.3%
2023	2023-12-31	USD -179.14	-26.2%
2024	2024-12-31	USD -137.61	-23.2%
2025	2025-12-31	USD -11.52	-91.6%

Curis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	45.6%
Q3	2025-09-30	27.9%
Q4	2025-12-31	351.0%
Q1	2026-03-31	-201.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$8.00K

-100.3%

Gross Margin

0.00%

N/A

Market Cap

$9.10M

N/A

Market Cap/Employee

$379.23K

N/A

Employees

N/A

Net Income

-$24.20M

-127.9%

EBITDA

-$24.19M

-129.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$15.00M

-26.0%

Total Debt

$1.34M

-49.3%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$108.00K

-91.9%

Short Term Debt

$1.23M

-5.5%

Return on Assets

-71.30%

N/A

Return on Invested Capital

-2.33%

N/A

Free Cash Flow

-$9.00M

-24.1%

Operating Cash Flow

-$9.00M

-24.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

HOTHHoth Therapeutics, Inc.

HOTHHoth Therapeutics, Inc.$0.80-4.48%

ICUSeaStar Medical Holding Corporation

ICUSeaStar Medical Holding Corporation$3.75+0.27%

BCTXBriaCell Therapeutics Corp.

BCTXBriaCell Therapeutics Corp.$3.58-3.76%

PCSAProcessa Pharmaceuticals, Inc.

PCSAProcessa Pharmaceuticals, Inc.$2.60-9.41%

CTXRCitius Pharmaceuticals, Inc.

CTXRCitius Pharmaceuticals, Inc.$0.52-2.07%

ENTOEntero Therapeutics, Inc.

ENTOEntero Therapeutics, Inc.$2.85-5.00%

ASBPAspire Biopharma Holdings, Inc.

ASBPAspire Biopharma Holdings, Inc.$7.26+0.69%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About CRIS

What is the current price of Curis?

Curis is trading at $4.90 per share.

What is the 52-week range for Curis?

Over the past 52 weeks, Curis has traded between $3.61 and $39.00.

How much debt does Curis have?

As of the most recent reporting period, Curis reported total debt of $1.34M.

How much cash does Curis have on hand?

Curis reported $15.00M in cash and cash equivalents in its most recent financial results.

What is Curis’s dividend yield?

Curis does not currently have a dividend yield.

Curis(NASDAQ) CRIS

Curis Financials at a Glance

CRIS News

Curis (CRIS) Q2 Loss Narrows 66%

Why Curis Stock Perked Up in August

Why Curis Fell Off a Cliff on Friday

Why Curis Stock Crashed on Thursday

Why Curis, Inc. Is Soaring Today

Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning

3 Top Stocks Under $5

Today’s Top Biotech Stories: Curis, Amgen, and Novartis

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Curis

Products and Services

Growth and Expansion

What Makes Curis Stand Out

Five Things You Need to Know

Bottom Line

CRIS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Curis Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CRIS

What is the current price of Curis?

What is the 52-week range for Curis?

How much debt does Curis have?

How much cash does Curis have on hand?

What is Curis’s dividend yield?

Premium Investing Services